We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Daiichi Seeks High Court Review Of Panel’s Reversal In Patent Drug Dispute

(September 16, 2015, 4:10 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court should review a drug patent infringement lawsuit over Apotex Inc.’s efforts to end Mylan Pharmaceuticals Inc.’s generic exclusivity for “Benicar” hypertension drug through a noninfringement decision, a drug manufacturer says in a Sept. 4 petition for certiorari, arguing that the lawsuit should be tossed based on Article III of the Constitution (Daiichi Sankyo, Inc. and Daiichi Sankyo Co., Ltd. v. Apotex, Inc., No. 15-281, U.S. Sup.).

(Petition for writ of certiorari available. Document #78-150921-009B.)

On March 31, the Federal...
To view the full article, register now.